The drug screening market is expected to reach USD 8.63 billion by 2022 from USD 5.32 billion in
2017, at a CAGR of 10.2%. Factors such as growing drug & alcohol
consumption, enforcement of stringent laws mandating drug and alcohol testing,
and the availability of government funding in major markets are driving the
growth of this market.
Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=162987773
Most key
players adopted product launches as the primary growth strategy between 2014
and 2017. Some of the companies that adopted this strategy include Alfa
Scientific Designs, Thermo Fisher, and Premier Biotech.
The drug
screening market is highly competitive with the presence of several big and
small players. Prominent players offering products for drug screening include Alere (US), Thermo Fisher (US), Drägerwerk
(Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc.
(US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (Germany).
While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada),
and CannAmm (Canada) are the leading players in the market.
Alere is a leader in the rapid
testing devices market because of the broad product portfolio if offers. Alere
provides oral fluid screening devices, urine drug testing devices, and breath
alcohol testing devices. The company also provides urine, oral, and hair drug
screening services for offices, drug treatment centers, pain management
centers, and hospitals. Serving such a wide range of customers will help the
company gain a competitive edge over other players in the market.
Alere focuses
on adopting both organic and inorganic growth strategies such as partnerships
and collaborations to maintain its leading position in the market. For
instance, in 2017, Alere (US) entered into partnership with MinuteClinic (US).
As per this agreement, MinuteClinic joined the Alere eScreen Occupational
Health Network (EOHN) and employees of those businesses that utilize Alere
eScreen’s services in more than 1,100 MinuteClinic locations in the US for
required workplace drug testing. Moreover, Alere has a strong geographic
presence across North America, Europe, the Middle East, Asia Pacific, Latin
America, and Africa. This strong network also enables Alere to distribute
products across the globe efficiently.
LabCorp is the leading player in the US drug screening services market.
The company has a strong brand value and a robust service portfolio. LabCorp
provides drug screening services to managed care organizations, governmental agencies,
physicians, and other healthcare providers, hospital and health systems,
employers, patient and consumers, contract research organizations, food and nutritional
companies, and independent clinical laboratories. The company has a strong
network of 39 laboratories and 1,700 patient service centers, and a network of
branches and STAT laboratories across the US, Canada, and the UK.
Over the past
three years, the company adopted acquisitions as its key growth strategy. For
instance, in 2017, LabCorp (US) acquires Bode Technology (UK). This enabled the company to expand its service
offerings in the drug screening services market.
To Know More @
No comments:
Post a Comment